On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) ...

Summary of PetVivo Holdings Conference Call Company Overview - **Company Name**: PetVivo Holdings - **Ticker Symbol**: PETV - **Market Focus**: Companion animal veterinary care market, valued at approximately $11 billion [2][19] Core Products - **Spryng with OsteoCushion Technology**: A veterinary medical device designed to restore joint mechanics and address osteoarthritis in animals. It is classified as a human medical device, allowing it to bypass FDA review for veterinary use [2][8]. - **PrecisePRP**: An allogenic freeze-dried platelet-rich plasma product, the only FDA-reviewed product for safety that does not require blood drawing from the animal [2][17]. Market Dynamics - **Osteoarthritis Prevalence**: Approximately 80% of dogs will develop osteoarthritis by age eight, with symptoms often starting as early as three to four years old [4]. - **Current Treatment Limitations**: Existing treatments primarily mask symptoms rather than address the root cause, leading to potential long-term damage [5][12]. Competitive Advantages - **Unique Mechanism of Action**: Spryng addresses the underlying issues of joint degradation rather than just alleviating pain, providing a longer-lasting solution (up to 12 months) compared to other treatments [6][8]. - **Cost-Effectiveness**: Spryng's pricing ranges from $600 to $1,200 per injection, which is competitive compared to monthly treatments like Librela costing around $150 [31][32]. - **Strong Intellectual Property Portfolio**: PetVivo holds 12 U.S. patents and 9 foreign patents, with ongoing efforts to expand this portfolio [3][9]. Distribution and Expansion - **Distribution Agreements**: Established partnerships with major distributors in the U.S. and recent expansions into Mexico and the UK [3][27]. - **Market Growth**: The pet care market is considered recession-proof, with increasing spending on veterinary care as pets are viewed as family members [19]. Clinical Evidence and Studies - **Successful Clinical Trials**: Over 12,000 injections have been administered with positive outcomes, including a study showing a 77% improvement in dogs with late-stage hip issues [10][15][16]. - **Ongoing Research**: Multiple clinical trials are underway, including studies at Colorado State University, aimed at further validating the efficacy of Spryng [16][24]. Future Outlook - **Product Pipeline**: Plans to expand into human markets and develop additional veterinary applications [22][29]. - **Regulatory Support**: The product has received endorsements from regulatory bodies, enhancing its credibility in the market [28]. Management and Team - **Experienced Leadership**: The management team includes individuals with extensive backgrounds in both veterinary and human healthcare sectors, contributing to the company's strategic direction [26][27]. Conclusion PetVivo Holdings is positioned to capitalize on the growing demand for effective veterinary treatments, particularly for osteoarthritis, through its innovative products and strong market presence. The company aims to leverage its unique technology and distribution partnerships to drive future growth and expand into new markets.

Core Viewpoint - PetVivo Holdings, Inc. is set to present at the Life Sciences Virtual Investor Forum on September 18, 2025, highlighting its innovative medical devices and therapeutics for animals [1][4]. Company Overview - PetVivo Holdings, Inc. is an emerging biomedical device company focused on the commercialization of medical devices and therapeutics for horses and companion animals [5]. - The company aims to leverage human therapies for animal treatment in a capital and time-efficient manner, with a strategy that allows for accelerated revenue timelines compared to pharmaceuticals [5]. Product Information - PetVivo has a robust pipeline of products, including SPRYNG™ with OsteoCushion™ technology for managing joint-related afflictions in animals and PrecisePRP, a first-in-class platelet-rich plasma product [6]. - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and production processes [6]. Event Details - The Life Sciences Virtual Investor Forum will take place on September 18, 2025, from 11:00 to 11:30 am ET, allowing real-time interaction between investors and the company [2]. - Archived webcasts will be available for those unable to attend the live event [2].

Core Points - PetVivo Animal Health, Inc. has entered into a distribution agreement with Nupsala Limited to market its veterinary medical device, Spryng with OsteoCushion technology, in the United Kingdom [1][2] - The distribution activities by Nupsala commenced on September 1, 2025, aiming to enhance the accessibility of Spryng to veterinarians and animal owners [1][2] - Spryng with OsteoCushion technology is designed to manage joint pain in animals by promoting proper joint mechanics and integrating with subsynovial tissue [3][4] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [5] - The company has a robust pipeline of products, including Spryng and PrecisePRP, and holds a portfolio of twenty-one patents protecting its biomaterials and methods [6] Partner Overview - Nupsala Limited specializes in musculoskeletal health and regenerative medicine for companion animals and horses, operating as both a veterinary wholesaler and referral provider [8][9] - Nupsala aims to improve animal mobility and deliver innovative solutions through clinical trials, diagnostics, and educational initiatives [9]

Financial Data and Key Metrics Changes - The company reported revenues of $298,000, representing a 141% increase compared to the same quarter last year [6][4] - Gross profit totaled $187,000, which is 63% of revenues, marking a 69% increase from $111,000 in the same quarter last year [7] - Operating loss decreased by 10% to $1,800,000 compared to the same quarter a year ago [8] - Net loss available to common stockholders was $2,300,000, or a negative loss of $0.09 per share, which is a 15% improvement from the previous year's net loss of $2,000,000 [8] - Available cash increased to $3,300,000 from $220,000 as of March 31, 2025 [9] - Total liabilities decreased by 39% to $1,200,000 during the quarter [9] Business Line Data and Key Metrics Changes - The U.S. National distributor network increased sales by 192% year-over-year, contributing $198,000 or 67% of total revenue [4][6] - The introduction of the new Precise PRP product alongside Spring contributed to the revenue increase [6] Market Data and Key Metrics Changes - The Mexican veterinary health care market is projected to grow at a compounded annual growth rate of 11%, reaching $2.4 billion by February 2031 [3] - The U.S. animal health market is expected to double to $11.3 billion by February 2030, providing significant growth opportunities [24] Company Strategy and Development Direction - The company is focused on expanding the adoption of its flagship product, Spring, and increasing awareness of Precise PRP for treating osteoarthritis in animals [12] - Strategic partnerships have been formed, including collaborations with Commonwealth Markets and Piezo BioMembrane, to enhance product offerings and market reach [20][22] - The company is integrating AI technology with its veterinary products to create a global pet care ecosystem [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for fiscal 2026 and beyond [24] - The company believes it is well-positioned to accelerate growth and expand into high-growth markets [24] Other Important Information - The company has recently qualified to trade on the OTCQX best market, enhancing visibility and liquidity for investors [11] - The commercialization of Spring and Precise PRP has received favorable feedback from veterinarians regarding their effectiveness [14] Q&A Session Summary - No questions were raised during the Q&A session, leading to the conclusion of the call [29][33]

Core Insights - PetVivo Holdings, Inc. reported a significant increase in revenues for the first quarter of fiscal year 2026, with total revenues reaching $298,000, marking a 141% increase compared to the same period last year [5][27][29] - The company is expanding its market presence, particularly in the companion animal sector, and has initiated international sales through a distribution agreement in Mexico [10][11][20] Fiscal Q1 Financial Highlights - Revenues increased to $298,000, a 141% rise year-over-year, driven by product line expansion and increased sales force efforts [5][27] - Gross profit rose 69% to $187,000, with a gross margin of 63% [5][28] - Operating loss decreased by 9% to $1.8 million, attributed to strategic restructuring and cost reduction initiatives [5][29] - Net loss increased 13% to $2.3 million, or $(0.09) per share, due to higher non-cash expenses [5][29] - Cash reserves increased to $3.3 million from $228,000 at the end of the previous quarter, primarily due to financing activities [5][30] - Total liabilities decreased by 39% to $3.1 million, mainly due to lease terminations and modifications of convertible note terms [5][31] Fiscal Q1 Operational Highlights - The company signed a distribution agreement with Eq Especialidades to promote Spryng™ in Mexico, marking its first international market entry [5][20] - A strategic partnership with PiezoBioMembrane aims to develop innovative biomaterials for tissue regeneration [5][24] - Collaboration with Digital Landia focuses on integrating AI technology to enhance veterinary care through real-time analysis of animal behavior [5][17] - Sales and marketing efforts are ramping up for the commercialization of PrecisePRP, a new product for treating osteoarthritis in animals [5][14] - A partnership with Commonwealth Markets integrates Spryng® and PrecisePRP into care protocols for thoroughbred horses [5][21] Industry Outlook - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [5][26] - The veterinary healthcare market in Mexico is expected to grow at a compounded annual growth rate of 11% to reach $2.4 billion by 2031 [10]

PART I [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) PetVivo Holdings, Inc. reported increased revenue to **$297,500** but a wider net loss of **$2.3 million** for the quarter ended June 30, 2025, with total assets decreasing to **$6.9 million** and cash increasing to **$3.3 million** from **$4.4 million** in financing, alongside a going concern warning [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, the company's total assets decreased to **$6.9 million** from **$9.3 million**, while cash and cash equivalents significantly increased to **$3.3 million** from **$228 thousand**, and total liabilities decreased to **$3.2 million** from **$5.1 million** Consolidated Balance Sheet Summary (Unaudited) | Metric | June 30, 2025 | March 31, 2025 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $3,303,844 | $227,689 | | Total Current Assets | $4,400,859 | $5,609,567 | | Total Assets | $6,890,496 | $9,339,195 | | **Liabilities & Equity** | | | | Total Current Liabilities | $3,117,433 | $4,316,800 | | Total Liabilities | $3,159,519 | $5,119,947 | | Total Stockholders' Equity | $3,730,977 | $4,219,248 | [Consolidated Statements of Operations](index=7&type=section&id=Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, revenues more than doubled to **$297,500** from **$123,751**, yet the net loss available to common stockholders increased to **$2.34 million** from **$2.05 million**, primarily due to **$466,720** in other expenses, despite an improved net loss per share of **($0.09)** Consolidated Statement of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenues | $297,500 | $123,751 | | Gross Profit | $186,726 | $110,757 | | Operating Loss | ($1,844,317) | ($2,044,432) | | Net Loss | ($2,311,037) | ($2,047,063) | | Net Loss Per Share (Basic and Diluted) | ($0.09) | ($0.11) | | Weighted Average Shares Outstanding | 24,302,790 | 18,683,975 | [Consolidated Statements of Cash Flows](index=9&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the three months ended June 30, 2025, the company used **$1.63 million** in operating cash, with **$4.71 million** provided by financing activities, primarily from **$4.4 million** in preferred stock proceeds, resulting in a net cash increase of **$3.08 million** and an ending cash balance of **$3.3 million** Consolidated Statement of Cash Flows Summary (Unaudited) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | ($1,633,755) | ($1,530,469) | | Net Cash Used in Investing Activities | $0 | ($15,178) | | Net Cash Provided by Financing Activities | $4,709,910 | $1,470,658 | | Net Increase (Decrease) in Cash | $3,076,155 | ($74,989) | | Cash at End of Period | $3,303,844 | $12,414 | [Notes to Financial Statements](index=10&type=section&id=Notes%20to%20Financial%20Statements) The notes detail accounting policies, including the termination of distribution agreements with MWI and Covetrus, new partnerships with Vedco and Clipper, a June 30, 2025 amendment to convertible notes reclassifying a **$768,493** derivative liability to equity, a **$314,768** lease termination fee, and reiterate the substantial doubt about the company's ability to continue as a going concern - The company mutually terminated its non-exclusive distribution agreements with **MWI Veterinary Supply Co.** in **March 2025** and **Covetrus North America LLC** in **February 2025**[38](index=38&type=chunk)[40](index=40&type=chunk) - New distribution partnerships were established with **Vedco, Inc.** and **Clipper Distributing, LLC** in **December 2024**[42](index=42&type=chunk) - On **June 30, 2025**, the company amended its convertible notes to fix the conversion price at **$0.50 per share**[78](index=78&type=chunk) - This modification was treated as a debt extinguishment, resulting in the re-measurement and reclassification of a **$768,493** derivative liability to additional paid-in capital and the recognition of a **$763,259** beneficial conversion feature[79](index=79&type=chunk)[81](index=81&type=chunk) - The company terminated its ten-year lease on a **14,073 square foot** production and warehouse space effective **June 30, 2025**, incurring total termination fees of **$314,768**[93](index=93&type=chunk) - The company has a history of net losses, negative operating cash flow, and an accumulated deficit of **$93.5 million**, which raises substantial doubt about its ability to continue as a going concern[99](index=99&type=chunk) - On **March 26, 2025**, the company entered into a subscription agreement for **$5 million** of Series B Preferred Stock[104](index=104&type=chunk) - The remaining **$4.4 million** was fully received and funded on **June 24, 2025**[104](index=104&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the **140%** year-over-year revenue growth to new Precise PRP product sales, but notes a wider net loss due to non-cash charges, with liquidity significantly boosted by a **$5 million** private placement of Series B preferred stock, though these funds are only sufficient until **December 31, 2025**, reinforcing the going concern risk and need for additional capital [Results of Operations](index=30&type=section&id=Results%20of%20Operations) Revenues for the three months ended June 30, 2025, increased to **$297,500** from **$123,751**, driven by **$149,257** in Precise PRP sales, while operating expenses decreased slightly to **$2.03 million** from **$2.16 million**, but the net loss increased to **$2.31 million** from **$2.05 million** due to **$466,720** in other expenses Results of Operations Comparison | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenues | $297,500 | $123,751 | | Cost of Sales | $110,774 | $12,994 | | Total Operating Expenses | $2,031,043 | $2,155,189 | | Net Loss | ($2,311,037) | ($2,047,063) | - The increase in revenues was primarily due to sales of **Precise PRP products**, which began following an exclusive licensing agreement with **VetStem**[143](index=143&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company had working capital of **$1.28 million** and cash of **$3.3 million**, achieved through a **$5 million** private placement of Series B convertible preferred stock, yet management believes this is insufficient for the next twelve months, necessitating additional capital - The company's working capital was **$1,283,426** as of **June 30, 2025**, with cash and cash equivalents of **$3,303,844**[151](index=151&type=chunk) - Net cash provided by financing activities was **$4.7 million**, primarily from **$4.4 million** in proceeds from the Series B preferred stock receivable[154](index=154&type=chunk) - Management states that despite the recent **$5 million** financing, they do not have sufficient cash for the next twelve months and will need to raise additional capital[152](index=152&type=chunk) [Going Concern](index=32&type=section&id=Going%20Concern) The company's financial statements include an explanatory paragraph from auditors expressing substantial doubt about its ability to continue as a going concern, as management believes the **$5 million** private placement proceeds are only sufficient to fund operations until **December 31, 2025** - The company's auditors have expressed **substantial doubt** about its ability to continue as a going concern[157](index=157&type=chunk) - Management believes the proceeds from the recent **$5 million** private placement are sufficient to fund operations only until **December 31, 2025**[157](index=157&type=chunk) [Qualitative and Quantitative Disclosures About Market Risk](index=33&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) This section is not required for the company as it qualifies as a smaller reporting company - Disclosure is not required as the company is a **smaller reporting company**[164](index=164&type=chunk) [Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in complex accounting for convertible notes and derivative liabilities, with remediation efforts expected to be completed before March 31, 2026 - Management concluded that disclosure controls and procedures were **not effective** as of **June 30, 2025**[165](index=165&type=chunk) - The ineffectiveness is due to **material weaknesses** related to the accounting for modifications of convertible notes, beneficial conversion features, warrant debt discounts, and derivative liabilities[165](index=165&type=chunk) - Remediation efforts are underway, including hiring additional accounting personnel, with an expected completion date prior to **March 31, 2026**[166](index=166&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not involved in any material legal proceedings outside of the ordinary course of business - The company is not currently involved in any **material legal proceedings**[169](index=169&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) The company states there have been no material changes to the risk factors previously disclosed in its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 - The company refers to the risk factors disclosed in its Annual Report on Form **10-K** for the fiscal year ended **March 31, 2025**, indicating no material updates[171](index=171&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=35&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the quarter, the company issued shares of common stock in several unregistered transactions, including for consulting services, RSU vesting, conversion of accounts payable, and a warrant exercise generating **$140,000** in proceeds - The company conducted several unregistered sales of equity securities during the quarter, including shares issued for consulting services in **April and May 2025**, shares issued upon the vesting of RSUs in **April and June 2025**, **8,000** shares issued to convert a **$6,000** accounts payable balance in **June 2025**, and **70,000** shares issued upon a warrant exercise, generating **$140,000** in proceeds in **June 2025**[172](index=172&type=chunk)[173](index=173&type=chunk)[174](index=174&type=chunk) [Defaults Upon Senior Securities](index=35&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - No defaults upon senior securities were reported[176](index=176&type=chunk) [Other Information](index=35&type=section&id=Item%205.%20Other%20information) The company reported no other information - No other information was reported[178](index=178&type=chunk) [Exhibits](index=36&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications as required by the Sarbanes-Oxley Act of 2002 and Inline XBRL data files - The report includes standard exhibits such as **CEO/CFO certifications** under Sections **302** and **906** of the **Sarbanes-Oxley Act**[180](index=180&type=chunk)

Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has successfully upgraded to trade on the OTCQX Best Market, enhancing its visibility and accessibility for investors [1][3][6] - The company specializes in innovative biomedical devices and therapeutics for horses and companion animals, with key products including SPRYNG with OsteoCushion Technology and PrecisePRP [1][4][5] Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of medical devices and therapeutics for equine and companion animals, leveraging human therapies for efficient treatment [7][8] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, indicating a strong intellectual property position [8] Product Details - SPRYNG with OsteoCushion Technology is an injectable veterinary medical device that aids in managing joint pain by restoring proper joint mechanics [4] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for veterinarians, providing a consistent dose of 4 billion platelets per vial [5]

Company Overview - PetVivo Holdings Inc. is an emerging biomedical device company based in Edina, Minnesota, focused on licensing and commercialization of innovative medical devices and therapeutics for equine and companion animals [5][6] - The company aims to leverage investments in human bio-materials and medical device industries to efficiently commercialize products for animals [5] - PetVivo has a robust pipeline of products, including twelve patents and six trade secrets protecting its biomaterials and methods [6] Market Position - PetVivo Holdings has upgraded to trade on the OTCQX Best Market from the OTCQB Venture Market, marking a significant milestone for the company [1][3] - Trading on OTCQX enhances the company's visibility within the investment community and provides greater liquidity and accessibility for investors [4] Product Offerings - The company's lead products include SPRYNG with OsteoCushion technology, an intra-articular injection for managing lameness and joint-related afflictions in animals, and PrecisePRP, a first-in-class platelet-rich plasma product for veterinary use [6]